Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

Recruiting

• Conditions: Opioid Use Disorder; Treatment Adherence and Compliance; Criminal Justice

• Registration Number: NCT06354465
• Lead Sponsor: Lifespan

Brief Summary

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-07-01
• Study First Submitted: 2024-03-31
• Status Verified: 2024-04
• Study First Submitted QC: 2024-04-04
• Last Update Submitted: 2024-04-04
• Study First Posted: 2024-04-09
• Last Update Posted: 2024-04-09
• Primary Completion: 2024-07-01
• Study Completion: 2024-07-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

• Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program

Organizational Stakeholders,

Exclusion Criteria

• If not permitted by their organizational union to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Qualitative Transcripts	1 year	A directed content analysis will identify key themes in structured interviews

Trial Locations

Locations (1)

Rhode Island Department of Corrections; 🇺🇸 Cranston, Rhode Island, United States